How far is China from a vaccine power?

Source: fenghuang.com 2013-10-08 at present, Sinopharm China Biotechnology Co., Ltd., China's largest vaccine manufacturer, is actively exploring overseas markets Due to its advantages of high quality and low price, Sinopharm's vaccines have been sold to South Korea, India, Nepal, Vietnam and other countries, and become the world's fifth largest vaccine supplier There are 85 vaccine manufacturers in the world and more than 40 in China China is also the world's largest vaccine producer, with an annual output of more than 1 billion vaccines Xiao Qiyou, deputy general manager of marketing center of China Biotechnology Co., Ltd., said that up to now, there are 40 vaccine manufacturers in China, which can produce 41 kinds of vaccines with a total dose of more than 1 billion doses, ranking first in the world In 2011, the vaccine market scale was 12.32 billion yuan At present, most domestic vaccine manufacturers are small in scale, lack of innovation and R & D capacity, and fierce market competition There are only 16 manufacturers of rabies vaccine and influenza vaccine In the current market share, private enterprises account for 41%, foreign enterprises account for 16%, and state-owned enterprises account for 43% State-owned enterprises refer to China Biotechnology Co., Ltd Wu Yonglin, deputy general manager of sinohealth, predicted that within 10 years, China's vaccine market will become the fastest growing market in global consumption, and also the most important vaccine production base in the world Vaccine manufacturers worldwide will compete most fiercely in China's market Most of the products produced in the efforts to go to the international market are first-class seedlings, which are priced and purchased by the government, free of charge to the public, with little profit In recent years, Zhongsheng company has developed several second-class vaccines The safety and effectiveness of the products have won the attention and praise of who, path and other international organizations Among them, the who issued the regulations on the manufacture of live attenuated encephalitis B vaccine, which is based on the production process and testing standards of Zhongsheng company Zhongsheng has enough ability to challenge the overseas market Xiao Qiyou said that at present, China's vaccine exports are mainly through bilateral channels of the government, registration by entrusted agents and procurement by international organizations The prerequisite for vaccine export is to pass the international certification system, FDA certification, EU certification, who pre certification, and obtain the registration and approval of the exporting country In 2011, China's vaccine regulatory system passed the evaluation of the World Health Organization, which means that Chinese vaccines are eligible to apply for the pre certification of the World Health Organization, enter the United Nations vaccine procurement plan, and supply the international market Yang Xiaoming, general manager of the company, said: "with the opportunity of who pre certification, the company intends to make every effort to promote the vaccine, and even the vaccine quality system in China, to fully integrate with the international standards." He believes that China's vaccine internationalization has a bright future, and "made in China" vaccines will definitely go to the international market While safeguarding the health of the Chinese people, we should also contribute to the health of the people of the world Zhongsheng company has its own intellectual property rights of viral vaccine products It was listed in China in 1988, and has been registered and sold in South Korea, Thailand, India, Vietnam and other Asian countries in recent 10 years So far, it has sold more than 300 million copies in China and 150 million copies overseas Zhongsheng, a vaccine power, is confident in the quality of its own vaccines "In the production of some mature vaccines, the quality of domestic vaccines is basically the same as that of the vaccines of multinational pharmaceutical companies," said the relevant person in charge of the company Vaccines are high-risk biological products, and there is no 100% safe vaccine In the past few years, the media reported that the problem of domestic vaccines has aroused strong public doubts As the largest vaccine production company in China, Zhongsheng company is puzzled, "if it affects the vaccination rate of class I vaccine, it will greatly reduce the level of infectious disease prevention of Chinese people." For this reason, the company has strict quality management, increased efforts in innovation, standardized production, strengthened supervision and made every effort to strengthen measures "Since 1919, the company has been a major producer of vaccinations in China Over the past 30 years, we have eradicated smallpox and polio, reducing measles, polio, pertussis, encephalitis B, meningitis, hepatitis A, tetanus, tuberculosis and 4 million deaths We are a responsible central enterprise The products we produce will be used for healthy children We must strictly control the quality " In recent years, breakthrough progress has been made in vaccine research and development in China, and the research and development capacity has been improved rapidly In 2012, China listed the first hepatitis E vaccine in the world Now, the hand oral vaccine of Zhongsheng company and the cervical cancer vaccine of Wantai company have entered the third phase of clinical practice In 2015, China's inactivated polio vaccine will also be put on the market, which will undoubtedly reduce the cases of abnormal reactions of oral sugar pills "China is not a vaccine power yet," said one insider "The low price setting of first-class vaccines in China has severely hit the innovation ability and enthusiasm of vaccine enterprises and hindered the upgrading work The proposal of "12th Five Year Plan for vaccine supply system construction" to appropriately increase the purchase price of class I vaccine will help to change this unreasonable situation " China is moving towards a vaccine power